The Bulletin
Men's Weekly


.

GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)

  • Written by PR Newswire

SHANGHAI and NEW ORLEANS, Nov. 28, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the preliminary safety and efficacy data from the Phase I study of GFH009 monotherapy for treatment of relapsed/refractory hematological...

The Bulletin Magazine

Your Reliable Partner for Every Roadside Emergency

Choosing Waterproofing Membranes for Outdoor Spaces: The Essential Attributes You Need

How Modular Content Accelerates Turnaround for Time-Sensitive Campaigns

How Litigation Lawyers in Sydney Can Help Resolve Disputes Efficiently

Revitalising Homes and Offices with Professional Carpet Cleaning Melbourne

Gum Grafting for Receding Gums: Cost, Recovery Time, and What to Expect

Why It’s Convenient to Buy Ceiling Fans Online

Creating Functional and Welcoming Spaces with a Professional Medical Clinic Fitout

10 Thoughtful Gift Ideas That Show You Truly Care

Debt Collection vs. Debt Recovery: What’s the Difference?

CHEAPER RIDES FOR FANS AS 13CABS CUTS FARES FOR FINALS WEEK

Therapeutic Approaches: CBT vs ACT for Depression